ArticleJournal of cancer research and clinical oncology2026

Comment on "Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?"

Manish R Bhise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.